

Provident Clinical Research

Kathleen Kelley, MD

kkelley@providentcrc.com • www.providentcrc.com

211 E. Lake Street
Addison, IL 60101
Tel: (630) 617-2000
Fax: (630) 617-2001

PROFESSIONAL EXPERIENCE:

2009-Present	Clinical Investigator Provident Clinical Research Addison, Illinois
2004-Present	Corporate Health/Employee Health Physician Edward Hospital Naperville, Illinois
2004-Present	Independent Physician Consultant MetLife Disability
2004-2005	Home Care Physician Rockford, IL
1994-2003	Clinic Physician OMNI Work Injury Clinic Glendale Heights, Illinois
1994-2003	Instructor of Occupational Medicine Hinsdale Hospital Hinsdale, Illinois
1988-2004	Urgent Care Physician Glen Ellyn Clinic Glen Ellyn, IL
1986-1988	Staff Physician Saran and Dan Medical Associates Downers Grove, IL

EDUCATION:

1982-1985	Internal Medicine Residency Loyola University Medical Center Maywood, Illinois
1982	Doctor of Medicine Medical College of Ohio Toledo, Ohio
1979	Bachelor of Arts in Psychology, Magna Cum Laude University of Toledo Toledo, Ohio

CERTIFICATION:

Current	Illinois State License
Current	American Board of Internal Medicine

PROFESSIONAL SOCIETIES:

1995-Present	Medical Review Officer-MROCC
1994-Present	American College of Occupational and Environmental Medicine

KEY ACCOMPLISHMENTS:

- Instructor in Occupational Medicine for nurse continuing education
 - Edward Hospital Naperville, Illinois

RESEARCH PARTICIPATION (CONFIDENTIAL INFORMATION REPRESENTED WITH XXX):

1. Effect of Nutritional Products on Metabolic Parameters in Subjects with Type 2 Diabetes (2010, Clinical Investigator) Sponsor: Abbott Nutrition, Abbott Laboratories
2. A Randomized, Controlled, Crossover Trial to Evaluate the Acute Bioavailability of XXX Products in Healthy Men (2010, Principal Investigator) Sponsor: Trygg Pharma, LLC
3. A Double-blind, Randomized, Placebo-controlled, Crossover Trial to Assess the Effects of 4 g/d XXX on Indices of Glucose Homeostasis and Lipoprotein Lipids in Subjects with Hypertriglyceridemia (2010, Clinical Investigator) Sponsor: Provident Clinical Research & Consulting, Inc.
4. Evaluation of a Snack Food Containing a Slowly Digestible Carbohydrate on Energy Intake and Satiety (2010, Clinical Investigator) Sponsor: GlaxoSmithKline Consumer Healthcare
5. A Randomized, Placebo-Controlled, Double-Blind, Crossover Study to Evaluate the Effects of Three Doses of the Dietary Ingredient, XXX Extract, on Alertness, Attention and Concentration in Healthy Men and Women (2010, Principal Investigator) Sponsor: DSM Nutritional Products Ltd

6. A Randomized, Double-blind, Placebo-controlled, Crossover Study Evaluating the Effects of a Fitness Beverage on Physical Performance in Healthy Male Volunteers (2010, Principal Investigator) Sponsor: PepsiCo, Inc.
7. Randomized, double-blind, placebo controlled Phase II study to examine the effects of XXX in healthy adult subjects with laboratory confirmed influenza (2010, Clinical Investigator) Sponsor: NexBio, Inc.
8. A Double-blind, Randomized, Placebo-controlled, Two-period Crossover Trial to Assess the Effects of 4g/d XXX on Low-density Lipoprotein Cholesterol and Other Aspects of the Fasting Lipid Profile in Subjects with Primary Hypercholesterolemia (2010, Clinical Investigator) Sponsor: Provident Clinical Research and Consulting, Inc.
9. A Randomized, Controlled, Double-blind Crossover Study to Assess the Effects of a Dietary Fiber Ingredient, at Two Doses, on Insulin Sensitivity (2009, Clinical Investigator) Sponsor: National Starch LLC
10. A Randomized, Controlled, Crossover Trial to Assess the Effects of Test Beverages on Work Capacity During Exercise in Trained Male Athletes (2009, Principal Investigator) Sponsor: The Coca-Cola Company
11. A Randomized, Controlled, Parallel Trial to Evaluate the Effects of Breakfast on Cognitive Processes in Children 8-12 Years of Age (2009, Principal Investigator) Sponsor: Kellogg Company
12. A Phase 3, Multi-Center, Placebo-Controlled, Randomized, Double-Blind, 12-Week Study to Evaluate the Effects of Two Doses of XXX on Fasting Serum Triglyceride Levels, in Patients With Persistent High Triglyceride Levels (≥ 200 mg/dL and < 500 mg/dL) Despite Statin Therapy (2009, Clinical Investigator) Sponsor: Amarin Pharma Inc.
13. "A Randomized, Controlled Crossover Study to Assess the Effects of Consuming XXX as Part of a Typical American Diet on the Plasma Lipid Profile in Men and Women with Primary Hypercholesterolemia" (2009, Principal Investigator) Sponsor: Almond Board of California
14. A Multicenter, Randomized, Double-Blind, Active Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of XXX in Combination with Metformin as Initial Therapy as Compared with XXX Monotherapy and Metformin Monotherapy in Subjects with Type 2 Diabetes Who Have Inadequate Glycemic Control (2009, Clinical Investigator) Sponsor: Bristol-Myers Squibb
15. A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of XXX Added to Antihypertensive Treatment with Lisinopril or Losartan in Patients with Hypertension (2009, Clinical Investigator) Sponsor: Forest Research Institute
16. "A Phase 3, Multi-Center, Placebo-Controlled, Randomized, Double-Blind, 12-Week Study With an Open-Label Extension to Evaluate the Efficacy and Safety of XXX in Patients With Fasting Triglyceride Levels ≥ 500 mg/dL and ≤ 2000 mg/dL: The XXX MARINE Study (2009, Clinical Investigator) Sponsor: Amarin Pharma Inc.
17. "A Multicenter, Randomized, Double-Blind, Active-Controlled Study to Evaluate the Durability of the Efficacy and Safety of XXX Compared to Glipizide When Used in Combination with Metformin in Subjects with Type 2 Diabetes" (2009, Clinical Investigator) Sponsor: Takeda

18. "A Randomized, Double-Blind, Placebo-Controlled, Parallel Arm Trial to Assess the Effects of XXX on High-Density Lipoprotein Cholesterol and Other Cardiovascular Disease Risk Markers" (2009, Clinical Investigator) Sponsor: Shaklee Corporation
19. "A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Long-Term Safety and Efficacy of XXX for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women" (2009, Clinical Investigator) Sponsor: BioSante Pharmaceuticals, Inc.
20. "A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Safety and Efficacy of XXX for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women" (2009, Clinical Investigator) Sponsor: BioSante Pharmaceuticals, Inc.
21. A Randomized, Placebo-Controlled, Crossover Trial to Assess the Effects of a Novel Dietary Supplement Preparation on Fasting Lipoprotein Lipids in Men and Women with Primary Hypercholesterolemia (Protocol B) (2009, Clinical Investigator) Sponsor: Pharmavite, LLC
22. A Randomized, Placebo-Controlled, Crossover Trial to Assess the Effects of a Dietary Supplement on Fasting Lipoprotein Lipids in Men and Women with Primary Hypercholesterolemia (Protocol A) (2009, Clinical Investigator) Sponsor: Pharmavite, LLC
23. A Randomized, Double-Blind, Active-Comparator, 8-Week Forced-Titration Study of the Efficacy and Safety of XXX Versus XXX in Hypertensive Subjects (2009, Clinical Investigator) Sponsor: Daiichi Sankyo, Inc.
24. Evaluation of the Relationships of Time and Dose of XXX and XXX to Changes in XXX of Red Blood Cells (2009, Clinical Investigator) Sponsor: Monsanto Company/The Solae Company
25. A Randomized, Controlled Parallel Study to Evaluate the Effects of XXX on Fecal Bile Acids and Blood Lipids in Men and Women with Mild to Moderate Hypercholesterolemia (2009, Clinical Investigator) Sponsor: The Solae Company
26. A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Exploratory, 28-Day Study to Examine the Effects of XXX on Blood Pressure and Glucose Tolerance in Patients With Mild to Moderate Hypertension and Impaired Glucose Tolerance (2009, Clinical Investigator) Sponsor: Arête Therapeutics
27. A Phase III, Double-blind, Randomized, Multi-Center, Prospective, Placebo-Controlled Comparative Study to Evaluate XXX on Carotid Intima-Media Thickness (cIMT) in Subjects with Type IIb Dyslipidemia with Residual Risk in Addition to Atorvastatin Therapy Trial. (2009, Clinical Investigator) Sponsor: Abbott Laboratories
28. A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel Group Study Evaluating the Efficacy, Safety and Pharmacokinetics of XXX Administered for 12 Weeks in Untreated or Metformin-treated Type 2 Diabetic Patients (BALANCE) (2009, Clinical Investigator) Sponsor: Akros Pharma Inc.
29. A Prospective, Open-Label, Titration Study to Evaluate the Efficacy and Safety of XXX in Multiple Subgroups of Hypertensive Subjects Who Are Non-Responders to Anti-Hypertensive Monotherapy (2009, Clinical Investigator) Sponsor: Daiichi Sankyo, Inc.

